We are live on
!
Find out more
Fayez Sarofim & Co Portfolio holdings
AUM
$39.1B
1-Year Est. Return
15.14%
This Fund
S&P 500
This Quarter
Est. Return
+5.34%
1 Year Est. Return
+15.14%
3 Year Est. Return
+57.14%
5 Year Est. Return
+86.44%
10 Year Est. Return
+281.86%
AUM
$43.1B
AUM Growth
+$1.45B
(+3.5%)
Cap. Flow
-$96.7M
Cap. Flow
% of AUM
-0.22%
Top 10 Holdings %
Top 10 Hldgs %
45.82%
Holding
319
New
11
Increased
71
Reduced
116
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$194M |
| 2 |
NVIDIA
NVDA
|
+$146M |
| 3 |
UnitedHealth
UNH
|
+$137M |
| 4 |
Meta Platforms (Facebook)
META
|
+$117M |
| 5 |
Philip Morris
PM
|
+$68.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$184M |
| 2 |
HES
Hess
HES
|
+$175M |
| 3 |
Nike
NKE
|
+$95.7M |
| 4 |
PepsiCo
PEP
|
+$94.4M |
| 5 |
Apple
AAPL
|
+$83.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.75% |
| 2 | Financials | 18.34% |
| 3 | Consumer Staples | 10.86% |
| 4 | Healthcare | 8.86% |
| 5 | Communication Services | 8.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Microsoft
MSFT
$2.91T
| $4.07B | 9.45% |
7,823,368
-28,310
| -0.4% | -$14.4M |
|
|
2
Apple
AAPL
$4.97T
| $3.93B | 9.11% |
15,366,927
-368,884
| -2% | -$83.3M |
|
3
Alphabet (Google) Class C
GOOG
$4.11T
| $1.87B | 4.33% |
7,606,218
+60,188
| +0.8% | +$12.7M |
|
4
Amazon
AMZN
$2.44T
| $1.8B | 4.18% |
8,155,023
+41,954
| +0.5% | +$9.5M |
|
|
5
Philip Morris
PM
$310B
| $1.8B | 4.17% |
11,085,935
+409,027
| +4% | +$68.8M |
|
|
6
NVIDIA
NVDA
$4.61T
| $1.56B | 3.61% |
8,243,611
+838,248
| +11% | +$146M |
|
|
7
Meta Platforms (Facebook)
META
$1.48T
| $1.42B | 3.3% |
1,925,483
+157,669
| +9% | +$117M |
|
8
JPMorgan Chase
JPM
$919B
| $1.1B | 2.56% |
3,470,400
-27,010
| -0.8% | -$8.03M |
|
|
9
Chevron
CVX
$383B
| $1.1B | 2.55% |
7,049,070
+1,252,527
| +22% | +$194M |
|
10
Coca-Cola
KO
$384B
| $1.1B | 2.55% |
16,567,084
-298,932
| -2% | -$20.6M |
|
11
Visa
V
$703B
| $1.05B | 2.43% |
3,040,212
-14,162
| -0.5% | -$4.9M |
|
12
ExxonMobil
XOM
$650B
| $1.04B | 2.42% |
9,249,009
-97,163
| -1% | -$10.8M |
|
13
McDonald's
MCD
$193B
| $842M | 1.95% |
2,755,414
+6,700
| +0.2% | +$2.04M |
|
14
Texas Instruments
TXN
$248B
| $758M | 1.76% |
4,096,612
-381,555
| -9% | -$74.6M |
|
15
Blackrock
BLK
$168B
| $746M | 1.73% |
635,156
-446
| -0.1% | -$499K |
|
16
S&P Global
SPGI
$124B
| $735M | 1.71% |
1,501,485
+6,857
| +0.5% | +$3.67M |
|
17
Procter & Gamble
PG
$340B
| $696M | 1.61% |
4,517,312
-92,421
| -2% | -$14.4M |
|
18
ASML
ASML
$599B
| $695M | 1.61% |
718,080
+12,754
| +2% | +$10M |
|
19
Mastercard
MA
$497B
| $665M | 1.54% |
1,160,271
+6,917
| +0.6% | +$3.97M |
|
20
Intuit
INTU
$91.3B
| $636M | 1.47% |
923,827
+26,615
| +3% | +$19.2M |
|
21
Abbott
ABT
$188B
| $609M | 1.41% |
4,515,964
-6,333
| -0.1% | -$831K |
|
22
TSMC
TSM
$1.94T
| $576M | 1.34% |
2,033,464
+32,509
| +2% | +$7.95M |
|
23
Progressive
PGR
$128B
| $549M | 1.27% |
2,213,309
+152,891
| +7% | +$37.7M |
|
|
24
UnitedHealth
UNH
$383B
| $548M | 1.27% |
1,570,342
+454,529
| +41% | +$137M |
|
25
Enterprise Products Partners
EPD
$83.7B
| $537M | 1.25% |
17,182,405
-323,280
| -2% | -$10.2M |
|
Similar funds
HF
Fayez Sarofim & Co's Q3 2025 Portfolio in Review
As of Q3 2025, Fayez Sarofim & Co held 319 positions worth $43.1B, up 3.5% from $41.7B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Fayez Sarofim & Co's Q3 2025 filing shows 11 new, 71 increased, 116 reduced and 14 closed positions. Its largest new stake was SAP: 49,674 shares worth $13.3M. The largest sale was Novo Nordisk, an estimated $184M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Financials and Consumer Staples.
- Fayez Sarofim & Co's largest Q3 2025 buy was SAP: 49,674 shares worth $13.3M.
- Fayez Sarofim & Co added most to Chevron in Q3 2025, an estimated $194M increase.
- Fayez Sarofim & Co's biggest Q3 2025 reduction was Novo Nordisk, cutting an estimated $184M.
- Fayez Sarofim & Co fully exited Hess in Q3 2025, selling an estimated $175M.
- Fayez Sarofim & Co's ten largest holdings make up 46% of its $43.1B portfolio in Q3 2025.
- Fayez Sarofim & Co opened 11 new positions and closed 14 in Q3 2025.
- Fayez Sarofim & Co's portfolio value rose 3.5% quarter-over-quarter to $43.1B.
Based on Fayez Sarofim & Co's 13F filing for Q3 2025, filed 14 Nov 2025.